Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase II Study of Capecitabine (Xeloda) Plus Conformal Radiotherapy for Patients With Locally Advanced, Non-Metastatic Rectosigmoid Carcinoma

NCT00216424 is registered in ClinicalTrials.gov with James A. Haley Veterans Administration Hospital as lead sponsor.

NCT NCT00216424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00216424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase II Study of Capecitabine (Xeloda) Plus Conformal Radiotherapy for Patients With Locally Advanced, Non-Metastatic Rectosigmoid Carcinoma
Lead sponsor
James A. Haley Veterans Administration Hospital
Phase
Phase 4
Overall status
Terminated
Start date
February 28, 2005
Completion date
January 31, 2007
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer